17:38 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Biohaven's BHV-0223 meets in Phase II/III for speaking anxiety

Biohaven Pharmaceuticals Holding Co. Ltd. (NYSE:BHVN) said BHV-0223 met the primary endpoint of reducing anxiety while performing an anxiety-provoking speech task vs. placebo in a U.S. Phase II/III trial to treat social anxiety disorder. The...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
02:08 , Nov 5, 2016 |  BioCentury  |  Finance

Craving Biohaven

Biohaven Pharmaceutical Holding Co. Ltd. raised a tranched $80 million private round on its management team’s track record of bringing neurology compounds through the clinic, and the range of both Orphan and common indications the...
23:13 , Nov 1, 2016 |  BC Extra  |  Financial News

Biohaven raises $80M round

Neurology company Biohaven Pharmaceutical Holding Co. Ltd. (Tortola, Virgin Islands) raised $80 million in an oversubscribed private round led by Venrock. Other participants included RA Capital, Vivo Capital, Aisling Capital , Rock Springs Capital, John...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Clinical News

BHV-0223: Phase I data

A Phase I trial in 10 subjects showed that single and multiple doses of sublingual BHV-0223 led to faster absorption and higher peak concentrations and greater absorption of riluzole on a dose-normalized basis vs. oral...